Irritable Bowel Syndrome – 20.01.CLI

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Bifidobacterium longum (BL) NCC3001 on Intestinal and Psychological Symptoms in Subjects with Irritable Bowel Syndrome (IBS)

Register Today!

Start DateOctober 2021
End DateJanuary 2022
Trial Duration10 weeks
Number of Visits4 visits + 1 phone call
Lead CRCRyan Imgrund